CANOPY GROWTH: Disappointing Q2 revenue numbers and another big loss | SELL | CAD11 VS. CAD12.5 (-25%)
CANOPY GROWTH - SELL | CAD11 VS. CAD12.5 (-25%)Disappointing Q2 revenue numbers and another big loss
Organic decline in revenues of 34%
Delay expected break-even
Focussed on building US presence
Canopy Growth is a licensed producer of medical marijuana in Canada. The principal activities of Co. are the production and sale of marijuana out of its facility in Smiths Falls, Ontario as regulated by the "Marijuana for Medical Purposes Regulations".
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.